Catalog No.
DHC90704
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
GA101, RG7159, RO5072759, afutuzumab, CAS: 949142-50-1
Clone ID
Obinutuzumab
A tale of two antibodies: obinutuzumab versus rituximab, PMID: 29741753
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions, PMID: 31166681
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma, PMID: 28976863
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial, PMID: 32305093
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial, PMID: 32888452
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial, PMID: 30522969
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial, PMID: 27345636
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, PMID: 24401022
Obinutuzumab, PMID: 29999701
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety, PMID: 29856692
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis, PMID: 32862749
The role of obinutuzumab in the management of follicular lymphoma, PMID: 31538821
Venetoclax-obinutuzumab: harnessing complexity, PMID: 32163557
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia, PMID: 31915195
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma, PMID: 28796588
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study, PMID: 31296423
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA, PMID: 33211799
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study, PMID: 29584548
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax, PMID: 32206772
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study, PMID: 30291335
Obinutuzumab in follicular lymphoma, PMID: 28276536
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia, PMID: 30862645
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies, PMID: 29716920
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma, PMID: 33022066
Obinutuzumab for the treatment of indolent lymphoma, PMID: 27117452
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial, PMID: 33181832
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study, PMID: 25634683
Clinical application of obinutuzumab for treating chronic lymphocytic leukemia, PMID: 31692500
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 31693429
Obinutuzumab for B-cell malignancies, PMID: 24856933
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal, PMID: 30547368
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study, PMID: 26282650
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy, PMID: 30341058
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial, PMID: 31462735
Obinutuzumab: what is there to learn from clinical trials?, PMID: 28584136
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma, PMID: 28324270
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia, PMID: 32795224
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA, PMID: 32505213
Obinutuzumab in hematologic malignancies: lessons learned to date, PMID: 26190254
Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders, PMID: 30668192
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples, PMID: 28407142
Impact of obinutuzumab alone and in combination for follicular lymphoma, PMID: 31360086
Obinutuzumab for the treatment of chronic lymphocytic leukemia, PMID: 24983589
Successful Treatment of Patients With Refractory PLA 2 R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases, PMID: 32311405
Obinutuzumab-related adverse events: A systematic review and meta-analysis, PMID: 33252145
Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy, PMID: 32954076
Obinutuzumab: a new class of anti-CD20 monoclonal antibody, PMID: 25014645
Role of obinutuzumab in the treatment of chronic lymphocytic leukemia, PMID: 25987688
Obinutuzumab for the treatment of lymphoproliferative disorders, PMID: 22283718
The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?, PMID: 32579408
For research use only. Not for human or drug use.
